
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc demonstrates a strong outlook due to its focused mission on addressing critical treatment gaps in osteosarcoma, supported by impressive preliminary survival data for its lead product, OST-HER2, in resected pulmonary metastatic cases. The company is well-positioned to capture a significant portion of the rapidly expanding veterinary oncology market, projected to grow from $1.58 billion in 2024 to $4.77 billion by 2034, reflecting sustained demand for targeted therapies. Furthermore, successful discussions with potential investors and regulatory specialists indicate robust momentum towards establishing a dedicated animal-health entity, enhancing OS Therapies' operational capabilities and market presence.
Bears say
OS Therapies Inc. recorded a substantial net operating loss of $6.9 million for the third quarter of 2025, amounting to $0.21 per share, which raises concerns about the company's financial sustainability amidst ongoing high expenditures. The continued investment in its listeria-based cancer immunotherapy programs, including OST-HER2, indicates a strategic focus on research and development, but such spending without revenue generation may hinder short-term financial stability. Additionally, operating at a net loss suggests challenges in achieving profitability in the near future, casting a shadow on potential investor sentiment towards the stock.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares